Search Results

1 - 10 of 1,147 items :

  • "chemotherapy" x
Clear All

-functioneaza-corpulomenesc/4050-epidemiologia-cancerelor-umane.html. [Last accessed on 2014 Nov 10]. 5. Sands MB, Dantoc BP, Hartshorn A, Ryan CJ, Lujic S. Single Question in Delirium (SQiD): Testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium. Palliat Med 2010;24:561-5. 6. Given B, Given CW. Older adults and cancer treatment. Cancer 2008;113(12 Suppl):3505-11. 7. Ian Olver. Chemotherapy for elderly patients with advanced cancer: is it worth it? Aust Prescr 2000;23:80-2. 8. Kumar A, Soares H, Balducci L, Djulbegovic B. Treatment

between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64 : 1751-6. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 2006; 24 : 669-76. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable

of chemotherapy-related medication errors. Am J Health Syst Pharm 2000; 57: S4-9. Mort D, Lansdown M, Smith N, Protopapa K, Mason M. For better, for worse? London: National Confidential Enquiry into Patient Outcome and Death; 2008. North East London Cancer Network NHS. Guidelines on the safe prescribing, handling and administration of cytotoxic drugs . London: Department of Health Publications; 2005. German Society of Oncology Pharmacy. Quality Standard for the Oncology Pharmacy Service with Commentary . 4 th Edition. Oldenburg: Onko-press; 2003. Adams V

inhibition: "Targeted" therapy for triple-negative breast cancer. Clin Cancer Res 2010; 16 : 4702-10. Wang XM, He JS, Tong JM. Clinical application of preoperative superselective intra-arterial chemotherapy in the treatment of late breast cancer cases. Journal of Surgery Concepts & Practice 2006; 11 : 136-8. Zuo WS. Modern molecular oncology of breast cancer . 2nd edition. Shandong: Shandong Science & Technology Press; 2006. p. 974-9. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy

References 1. Bear HD. Indication for neoadjuvant chemotherapy for breast cancer. Semin Oncol. 1998; 25(2 Suppl3):3-12. 2. Botti C,Vici P, Lopez M, Scinto AF, Cognetti F, Cavaliere R. Prognotic value of lymph node metastasis after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am CollSurg. 1995; 181 (3):202-208. 3. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast

References 1. Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009; 23:655-74. 10.1016/j.hoc.2009.04.009 2. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation N Engl J Med. 2009; 360:2730-41. 3. Holdsworth MT, Raisch DW, Winter SS, Chavez CM. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Support Care Cancer. 1998; 6:132-8. 10.1007/s005200050147 4. Langston WT, Wathen JE

Introduction Drug resistance is a wide spread and well known phenomenon among anticancer medications and platinum drugs are not exceptions. The use of these drugs in chemotherapy is hampered by extrinsic and intrinsic resistance of cells. Although many cancer cells are initially susceptible to chemotherapy with platinum drugs, over time they may develop resistance through more efficient DNA damage repair, drug inactivation with glutathione and metallothioneins and drug efflux with various transport systems located in cell membrane. In this review the chemical

References Anonymous (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on reccurrence and 15-year survival: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet , 365 (9472), 1687-1717. De Laurentiis, M., Caputo, F., Massarelli, E., Forestieri, V., Vernaglia, A., Carlomagno, C., Lauria, R., Bianco, A. R., De Placido, S. (2001). HER2 expression and anthracycline effect: Results from the Naple GUN 3 randomized trial. Proc. Am. Soc. Clin. Oncol. , 20, 34A (abstract 133). Dressler, L. G

Introduction The standard treatment of patients with advanced epithelial ovarian cancer is a combination of primary surgery followed by chemotherapy. In the recent years it became clear that the goal of surgery is to achieve no macroscopic residual disease, since the survival of patients with no residual disease is superior to survival of patients with visible residual disease. 1 To achieve this goal, several aggressive surgical techniques have been proposed. Often multivisceral resections are performed (diaphragm resection, splenectomy, colon resection

half of the elderly patients with stage III colon cancer do not receive chemotherapy, although most of the studies and meta-analysis have reported similar response rate (ORR), overall survival (OS), time to progression (TTP) and tolerability for elderly and younger patients in adjuvant and metastatic setting. 4 - 6 Addition of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, to the chemotherapy backbone regimens improves progression-free survival (PFS) and overall survival in first-line and second-line treatment and when